{"Welcome.html": {"id": "Welcome.html", "text": "Welcome", "displayed_text": "Welcome"}, "Task.html": {"id": "Task.html", "text": "Task", "displayed_text": "Task"}, "Causality.html": {"id": "Causality.html", "text": "Causality", "displayed_text": "Causality"}, "Causality Examples.html": {"id": "Causality Examples.html", "text": "Causality Examples", "displayed_text": "Causality Examples"}, "Navigation.html": {"id": "Navigation.html", "text": "Navigation", "displayed_text": "Navigation"}, "Consent.html": {"id": "Consent.html", "text": "Consent", "displayed_text": "Consent"}, "Medicine_tweet_13_p": {"DOI": "10.1002/cncr.30564", "id": "Medicine_tweet_13_p", "News Finding": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Finding": "Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status.", "News Context": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Context": "Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.", "scores": "[5.0, 2.0, 1.0, 3.0, 5.0]", "field": "Medicine", "split": "val", "final_score": 5.0, "source": "tweets", "News URL": "834783376150249472", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.\"><b>Finding:</b></span> Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.\"><b>Finding:</b></span> Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status."}, "Medicine_56_r": {"DOI": "10.1001/jama.2014.15690", "id": "Medicine_56_r", "News Finding": "At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).", "Paper Finding": "The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).", "News Context": "The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.", "Paper Context": "Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).", "scores": "[5.0, 5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.75, "source": "news", "News URL": "http://www.newswise.com/articles/effect-of-once-daily-low-dose-aspirin-on-cv-death-and-other-outcomes", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.\"><b>Finding:</b></span> At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.\"><b>Finding:</b></span> At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent)."}, "Medicine_56_p": {"DOI": "10.1001/jama.2014.15690", "id": "Medicine_56_p", "News Finding": "At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).", "Paper Finding": "The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).", "News Context": "The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.", "Paper Context": "Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).", "scores": "[5.0, 5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.75, "source": "news", "News URL": "http://www.newswise.com/articles/effect-of-once-daily-low-dose-aspirin-on-cv-death-and-other-outcomes", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).\"><b>Finding:</b></span> The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).\"><b>Finding:</b></span> The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54)."}, "Medicine_tweet_68_r": {"DOI": "10.1001/jamapediatrics.2018.0302", "id": "Medicine_tweet_68_r", "News Finding": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Finding": "Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not.", "News Context": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Context": "We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.", "scores": "[4.0, 2.0, 5.0, 2.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "tweets", "News URL": "1001559206733012993", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. \"><b>Finding:</b></span> #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. \"><b>Finding:</b></span> #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. "}, "Medicine_tweet_68_p": {"DOI": "10.1001/jamapediatrics.2018.0302", "id": "Medicine_tweet_68_p", "News Finding": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Finding": "Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not.", "News Context": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Context": "We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.", "scores": "[4.0, 2.0, 5.0, 2.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "tweets", "News URL": "1001559206733012993", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks\\' gestation) improved birth weight, but early supplementation (initiation at <20 weeks\\' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.\"><b>Finding:</b></span> Late vitamin D supplementation (initiation at \u226520 weeks\\' gestation) improved birth weight, but early supplementation (initiation at <20 weeks\\' gestation) did not.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.\"><b>Finding:</b></span> Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not."}, "test_question_testing_Correlation": {"id": "test_question_testing_Correlation", "text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Correlation. Do not mark any words or phrases.", "displayed_text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Correlation. Do not mark any words or phrases."}, "Medicine_71_r": {"DOI": "10.1136/annrheumdis-2013-203804", "id": "Medicine_71_r", "News Finding": "Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition.", "Paper Finding": "The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).", "News Context": "With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.", "Paper Context": "Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .", "scores": "[4.0, 5.0, 4.0, 4.0]", "field": "Medicine", "split": "test", "final_score": 4.25, "source": "news", "News URL": "http://ct.moreover.com/?a=39498153871&p=1pl&v=1&x=ABngbXsk5KufxyHrE-m2mg", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it\\'s a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.\"><b>Finding:</b></span> Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it\\'s a common condition.']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.\"><b>Finding:</b></span> Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition."}, "test_question_testing_No mention of a relation": {"id": "test_question_testing_No mention of a relation", "text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select No mention of a relation. Do not mark any words or phrases.", "displayed_text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select No mention of a relation. Do not mark any words or phrases."}, "Medicine_71_p": {"DOI": "10.1136/annrheumdis-2013-203804", "id": "Medicine_71_p", "News Finding": "Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition.", "Paper Finding": "The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).", "News Context": "With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.", "Paper Context": "Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .", "scores": "[4.0, 5.0, 4.0, 4.0]", "field": "Medicine", "split": "test", "final_score": 4.25, "source": "news", "News URL": "http://ct.moreover.com/?a=39498153871&p=1pl&v=1&x=ABngbXsk5KufxyHrE-m2mg", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .\"><b>Finding:</b></span> The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .\"><b>Finding:</b></span> The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%)."}, "Medicine_tweet_0_r": {"DOI": "10.1001/jama.2018.20578", "id": "Medicine_tweet_0_r", "News Finding": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Finding": "Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding.", "News Context": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Context": "The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.", "scores": "[5.0, 5.0, 5.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 5.0, "source": "tweets", "News URL": "1087877579288297472", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  \"><b>Finding:</b></span> This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  \"><b>Finding:</b></span> This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  "}, "Medicine_tweet_0_p": {"DOI": "10.1001/jama.2018.20578", "id": "Medicine_tweet_0_p", "News Finding": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Finding": "Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding.", "News Context": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Context": "The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.", "scores": "[5.0, 5.0, 5.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 5.0, "source": "tweets", "News URL": "1087877579288297472", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.\"><b>Finding:</b></span> Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.\"><b>Finding:</b></span> Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding."}, "Medicine_tweet_153_r": {"DOI": "10.1111/jth.13811", "id": "Medicine_tweet_153_r", "News Finding": "SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia", "Paper Finding": "Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible.", "News Context": "SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia", "Paper Context": "\u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible. \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI.", "scores": "[3.0, 4.0, 4.0, 3.0]", "field": "Medicine", "split": "val", "final_score": 3.5, "source": "tweets", "News URL": "939058643814756352", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia\"><b>Finding:</b></span> SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia\"><b>Finding:</b></span> SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia"}, "Medicine_tweet_153_p": {"DOI": "10.1111/jth.13811", "id": "Medicine_tweet_153_p", "News Finding": "SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia", "Paper Finding": "Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible.", "News Context": "SPINART 3 year randomised study Tertiary Prophy vs On demand in adults with #haemophilia. With prophy 94% less bleeds. 1/3 no bleeds at all, 3/4 &lt;2 bleeds per year. Higher quality of life. No change in MRI - bony changes are irreversible.  #hemophilia", "Paper Context": "\u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible. \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI.", "scores": "[3.0, 4.0, 4.0, 3.0]", "field": "Medicine", "split": "val", "final_score": 3.5, "source": "tweets", "News URL": "939058643814756352", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible. \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI.\"><b>Finding:</b></span> Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible. \u2022 Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI.\"><b>Finding:</b></span> Conclusions: Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that preexisting joint arthropathy may be irreversible."}, "Medicine_161_r": {"DOI": "10.1038/s41467-018-04648-0", "id": "Medicine_161_r", "News Finding": "\"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\"", "Paper Finding": "These regions may play a critical role in transducing peripheral inflammatory signals to the central changes seen in rheumatoid arthritis.", "News Context": "\"This intriguing data supports the idea that rheumatoid arthritis inflammation targets the brain and not just the joints,\" Basu says. \"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\" Because this is one of the first studies to examine brain inflammation in rheumatoid arthritis, Schrepf says, additional research is needed on the correlation.", "Paper Context": "A graph theoretical analysis of whole-brain functional connectivity revealed a pattern of connections spanning 49 regions, including the IPL and medial frontal cortex, that are associated with peripheral inflammation. These regions may play a critical role in transducing peripheral inflammatory signals to the central changes seen in rheumatoid arthritis. These changes tend to be conserved across mammalian species and include increased sensitivity to pain, fatigue and cognitive dysfunction.", "scores": "[5.0, 4.0, 4.0]", "field": "Medicine", "split": "val", "final_score": 4.333333333333333, "source": "news", "News URL": "http://ct.moreover.com/?a=34334472687&p=1pl&v=1&x=4AUPMIcZw56G8088fDCfzQ", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: \"This intriguing data supports the idea that rheumatoid arthritis inflammation targets the brain and not just the joints,\" Basu says. \"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\" Because this is one of the first studies to examine brain inflammation in rheumatoid arthritis, Schrepf says, additional research is needed on the correlation.\"><b>Finding:</b></span> \"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\"']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: \"This intriguing data supports the idea that rheumatoid arthritis inflammation targets the brain and not just the joints,\" Basu says. \"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\" Because this is one of the first studies to examine brain inflammation in rheumatoid arthritis, Schrepf says, additional research is needed on the correlation.\"><b>Finding:</b></span> \"By relating these advanced neuroimaging measures back to the patient experience, we provide evidence that the future targeting of central inflammatory pathways may greatly enhance the quality of life of patients with rheumatoid arthritis and potentially other chronic inflammatory disorders.\""}, "Experience.html": {"id": "Experience.html", "text": "Experience", "displayed_text": "Experience"}, "End.html": {"id": "End.html", "text": "End", "displayed_text": "End"}}